Fig. 3From: Eculizumab in gemcitabine-induced thrombotic microangiopathy: experience of the French thrombotic microangiopathies reference centreEvolution of renal function as a function of time in the eculizumab group and in the control group. Values expressed as mean and standard deviationsBack to article page